Aims Although debates over the efficacy of oral naltrexone and acamprosate in treating
alcohol use disorders tend to focus on their global efficacy relative to placebo or their …

Aims To ascertain the efficacy and safety of naltrexone and acamprosate in the treatment of
alcohol dependence. Methods Systematic review of the literature (1990–2002) and meta …

Aims To determine the efficacy of acamprosate and naltrexone in the treatment of those who
are alcohol‐dependent in reducing lapse/relapse to alcohol consumption and treatment …

Importance Alcohol use disorder affects more than 28.3 million people in the United States
and is associated with increased rates of morbidity and mortality. Objective To compare …

Importance Alcohol use disorders cause substantial morbidity and early mortality yet remain
greatly undertreated. Medications are considerably underused. Objective To conduct a …

Background: Renewed interest in medications to prevent relapse in alcoholics (ie,
antidipsotropics) resulted in approval by the Food and Drug Administration of naltrexone to …

Two pharmacological agents have repeatedly been shown to be efficacious for relapse
prevention in alcohol dependence: The putative glutamate-antagonist acamprosate and the …

Aim To compare the efficacy of acamprosate and naltrexone in the treatment of alcohol
dependence. Design A double‐blind, placebo‐controlled trial. Setting Three treatment …

ContextAlcoholism affects approximately 10% of Americans at some time in their lives.
Treatment consists of psychosocial interventions, pharmacological interventions, or both, but …

Background: In almost 2 decades of naltrexone research for treating alcoholism, there have
been 29 published randomized placebo-controlled trials of opioid antagonists, primarily …